NCT03420521 2024-01-09
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
Clinical Trials
8 trialsNCT02859064 2023-12-05
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT01165658 2020-01-02
Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02177773 2019-11-12
DOTA-TOC
University of California, San Francisco
Phase 1/2 Terminated
NCT00227136 2018-04-13
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
Western University, Canada
Phase 3 Terminated
NCT02359500 2017-05-03
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Icahn School of Medicine at Mount Sinai
Phase 1 Terminated
NCT00947167 2017-03-03
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT01271959 2012-10-05
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
Precision Therapeutics
Terminated